Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitus

Takeda Pharma GmbH0 个研究点开始时间: 2006年8月10日最近更新: 2012年3月19日

试验速览

暂无简介。

•Patients with type 2 diabetes mellitus, HbA1c > 6,5%, but < 8,5% and/ or fasting plasma glucose > 7 mmol/l, male or female, age 30-75 years, inefficiently treated with Glimepiride monotherapy (1-3 mg) 3 months before entering the study, patients having signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Type 1 diabetes mellitus, hypersensitivity to the study drugs, progressive fatal disease, more than one unexplained episode of severe hypoglycaemia within 6 months prior to study entry, history of significant cardiovascular (NYHA I-IV), respiratory, gastrointestinal, hepatic, renal, neurological, psychatric and/ or hematological disease, lack of compliance, pretreatment with thiazolidinedions within the last 12 months, pretreatment with other anti-diabetic drugs than Glimepiride within the last 3 months

发起方

Takeda Pharma GmbH